Palvella Therapeutics
-
Wayne-Based Palvella Shares Soar as Lead Drug Candidate Meets Trial Goals
Wayne-based Palvella Therapeutics stock jumped 35 percent following the announcement of positive late-stage testing for Qtorin rapamycin, its lead drug candidate for a rare skin disease, writes John George for the Philadelphia…
-
Wayne’s Palvella Therapeutics Completes Reverse Merger with Pieris Pharmaceutical
Wayne-based Palvella Therapeutics recently finalized a reverse merger with Pieris Pharmaceutical, transitioning into a publicly traded company while securing a significant cash infusion, writes John…
-
Wayne-based Palvella Therapeutics Poised to Go Public Later This Year
Wayne-based Palvella Therapeutics is poised to go public later this year through a reverse merger deal with Boston-based Pieris Pharmaceuticals, writes John George for the…
-
Three Chester County Biopharmaceutical, Medtech Companies Net New Deals or Receive Approvals
Last week has been a productive one for Chester County biopharmaceutical and medical technology companies, writes John George for the Philadelphia Business Journal. Wayne-based Palvella…
Pioneer Partner
Founding Partners
Advertisement
Affiliate Partners
Community Partners
